Morgan Stanley’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-506
| Closed | -$1K | – | 6968 |
|
|
2020
Q2 | $1K | Buy |
506
+78
| +18% | +$148 | ﹤0.01% | 6567 |
|
|
2020
Q1 | $0 | Sell |
428
-334
| -44% | -$682 | ﹤0.01% | 6846 |
|
|
2019
Q4 | $2K | Buy |
762
+534
| +234% | +$1.71K | ﹤0.01% | 6533 |
|
|
2019
Q3 | $1K | Sell |
228
-4
| -2% | -$27 | ﹤0.01% | 6601 |
|
|
2019
Q2 | $2K | Sell |
232
-428
| -65% | -$7.88K | ﹤0.01% | 6499 |
|
|
2019
Q1 | $18K | Sell |
660
-8,588
| -93% | -$219K | ﹤0.01% | 6045 |
|
|
2018
Q4 | $209K | Sell |
9,248
-4,403
| -32% | -$172K | ﹤0.01% | 5270 |
|
|
2018
Q3 | $753K | Buy |
13,651
+6,572
| +93% | +$420K | ﹤0.01% | 4736 |
|
|
2018
Q2 | $505K | Buy |
7,079
+937
| +15% | +$66.2K | ﹤0.01% | 5093 |
|
|
2018
Q1 | $377K | Buy |
6,142
+437
| +8% | +$38.4K | ﹤0.01% | 5155 |
|
|
2017
Q4 | $719K | Sell |
5,705
-2,267
| -28% | -$290K | ﹤0.01% | 4761 |
|
|
2017
Q3 | $1.09M | Sell |
7,972
-12,099
| -60% | -$1.62M | ﹤0.01% | 4366 |
|
|
2017
Q2 | $2.86M | Buy |
20,071
+4,185
| +26% | +$647K | ﹤0.01% | 3450 |
|
|
2017
Q1 | $2.92M | Buy |
15,886
+8,396
| +112% | +$941K | ﹤0.01% | 3461 |
|
|
2016
Q4 | $603K | Buy |
7,490
+4,903
| +190% | +$388K | ﹤0.01% | 4807 |
|
|
2016
Q3 | $198K | Buy |
2,587
+1,373
| +113% | +$110K | ﹤0.01% | 5032 |
|
|
2016
Q2 | $104K | Sell |
1,214
-1,568
| -56% | -$144K | ﹤0.01% | 5225 |
|
|
2016
Q1 | $257K | Buy |
2,782
+1,868
| +204% | +$187K | ﹤0.01% | 4836 |
|
|
2015
Q4 | $183K | Sell |
914
-878
| -49% | -$175K | ﹤0.01% | 5135 |
|
|
2015
Q3 | $268K | Sell |
1,792
-61
| -3% | -$44.8K | ﹤0.01% | 4944 |
|
|
2015
Q2 | $1.76M | Buy |
1,853
+1,256
| +210% | +$1.03M | ﹤0.01% | 3739 |
|
|
2015
Q1 | $438K | Sell |
597
-3,619
| -86% | -$2.72M | ﹤0.01% | 4754 |
|
|
2014
Q4 | $3.35M | Buy |
4,216
+3,675
| +679% | +$1.98M | ﹤0.01% | 3096 |
|
|
2014
Q3 | $215K | Buy |
541
+282
| +109% | +$75.5K | ﹤0.01% | 5107 |
|
|
2014
Q2 | $70K | Sell |
259
-147
| -36% | -$31.5K | ﹤0.01% | 5642 |
|
|
2014
Q1 | $88K | Sell |
406
-28
| -6% | -$7.8K | ﹤0.01% | 5501 |
|
|
2013
Q4 | $118K | Buy |
+434
| New | +$103K | ﹤0.01% | 5284 |
|
|
2013
Q3 | – | Sell |
-4,055
| Closed | -$570K | – | 5424 |
|
|
2013
Q2 | $570K | Buy |
+4,055
| New | +$642K | ﹤0.01% | 4168 |
|
Morgan Stanley's TTPH Position: Q3 2020 in Review
Morgan Stanley sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 506 shares — an estimated $1K sold.
Morgan Stanley first reported a position in TTPH in Q2 2013 and held it in 28 quarters. The position peaked at $3.35M in Q4 2014. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Morgan Stanley reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Morgan Stanley sold 506 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1K.
- Morgan Stanley first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 28 quarters.
- Morgan Stanley's Tetraphase Pharmaceuticals, Inc. position peaked at $3.35M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Morgan Stanley's 13F filing for Q3 2020, filed 13 Nov 2020.